Inhalte

For a variety of malignant hematological diseases, hematopoietic stem cell transplantation is the only curative treatment option and the last hope for many leukemia patients. However, more than half of the patients die within the first two years after transplantation because of tumor relapse or graft versus host disease (GVHD). Therefore, there is an urgent medical need for novel treatment strategies in this area for new therapeutic approaches. We identified a new approach by therapeutically inhibiting specific genes which are expressed during GVHD-related pathological angiogenesis. In disease-specific mouse models we will test the efficacy of this novel approach in inhibiting tumor growth by using state-of-the art methods as immune status assessment via flow cytometry and immunofluorescence microscopy. The course will be divided in practical lab sessions, data analysis sessions and background seminars, concluding with a final data presentation in an internal symposium.

Kontakt

katarina.riesner@charite.de

Link zum Vorlesungsverzeichnis

folgt